Get the Stockscreener App
0.9111
4.60%
-0.0439
After Hours:
1.76
0.8489
+93.17%
Biocardia Inc stock is traded at $0.9111, with a volume of 140.75K.
It is down -4.60% in the last 24 hours and down -21.46% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$0.955
Open:
$0.95
24h Volume:
140.75K
Relative Volume:
0.91
Market Cap:
$10.36M
Revenue:
$3,000
Net Income/Loss:
$-8.23M
P/E Ratio:
-0.6458
EPS:
-1.4107
Net Cash Flow:
$-7.44M
1W Performance:
-4.19%
1M Performance:
-21.46%
6M Performance:
-36.29%
1Y Performance:
-53.75%
1-Day Range:
$0.9102
$0.97
1-Week Range:
$0.8807
$0.97
52-Week Range:
$0.8404
$2.45
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.50 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.54 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia outlines Japan Shonin filing in ~7 months and targets ~19-month path to approval for CardiAMP - MSN
BioCardia CEO Peter Altman buys $1,570 in company stock - Investing.com
BioCardia (NASDAQ: BCDA) CEO adds 1,700 shares in May open‑market buys - Stock Titan
BioCardia reports positive results from CardiAMP CMI trial By Investing.com - Investing.com Nigeria
BioCardia Announces Positive CardiAMP Chronic Myocardial Ischemia Trial Results with Reduced Angina at EuroPCR 2026 - Minichart
BioCardia reports positive results from CardiAMP CMI trial - Investing.com UK
BioCardia Announces Encouraging CardiAMP Chronic Ischemia Data - TipRanks
BioCardia reports durable exercise gains, 82% angina reduction in CardiAMP CMI open-label cohort - TradingView
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - The Manila Times
BioCardia (NASDAQ: BCDA) posts CardiAMP CMI data with durable angina and exercise gains - Stock Titan
Heart cell therapy linked to longer walks, 82% fewer angina attacks - Stock Titan
BioCardia president and CEO Peter Altman buys $5,244 in stock By Investing.com - Investing.com Nigeria
BioCardia, Inc. (NASDAQ:BCDA) Q1 2026 Earnings Call Transcript - Insider Monkey
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - The Manila Times
Watch BioCardia’s virtual fireside chat at A.G.P. healthcare showcase - Stock Titan
BioCardia Reports Promising CardiAMP Cell Therapy Data in Q1 2026 Conference Call - IndexBox
BioCardia president and CEO Peter Altman buys $5,244 in stock - Investing.com UK
BioCardia (BCDA) CEO buys 5,700 shares in open-market purchase - Stock Titan
BioCardia (BCDA) Q1 2026 Earnings Transcript - AOL.com
BioCardia Q1 2026: -$0.21 EPS Falls Short — Deep Dive - AlphaStreet
BCDA Stock Price, Quote & Chart | BIOCARDIA INC (NASDAQ:BCDA) - ChartMill
Q1 2026 BioCardia Inc Earnings Call Transcript - GuruFocus
BioCardia, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ... By GuruFocus - Investing.com Canada
Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths - TradingView
BioCardia (BCDA) Q1 2026: EPS Not Disclosed, Revenue Not Disclos - GuruFocus
BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthro - GuruFocus
Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus
Earnings call transcript: Biocardia Q1 2026 highlights clinical progress By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys $5,202 in company stock - Investing.com
BioCardia CEO Peter Altman buys $5,202 in company stock By Investing.com - Investing.com South Africa
BCDA: CardiAMP therapy advances toward Japanese approval, targeting a $400M market with strong clinical data - TradingView
Earnings call transcript: Biocardia Q1 2026 highlights clinical progress - Investing.com UK
BioCardia (BCDA) CEO Peter Altman makes open-market stock purchase - Stock Titan
BioCardia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCardia Q1 2026 Earnings Call: Complete Transcript - Benzinga
BCDA - Finviz
MSN Money - MSN
BioCardia Releases Q1 2026 Financial Results - AlphaStreet
BioCardia, Inc. (BCDA) Files Form 8-K: Financial Results, SEC Disclosures, and NASDAQ Listing for May 2026 - Minichart
BioCardia Inc (NASDAQ:BCDA) Q1 Earnings Miss Overshadows Clinical Progress - ChartMill
BIOCARDIA ($BCDA) Releases Q1 2026 Earnings - Quiver Quantitative
BioCardia reports Q1 2026 net loss of $2.3M, cash $951K and ongoing regulatory progress - TradingView
BCDA: Advanced regulatory milestones and improved financials, but cash reserves declined - TradingView
BioCardia, Inc. 1Q 2026: Net loss $(2.26)M, EPS $(0.21) — 10-Q Summary - TradingView
BioCardia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):